Surface Oncology
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Surface Oncology generated cash of -$59,552,000, which is more than the previous year. Cash used in financing activities reached the amount of $31,660,000 last year. Net change in cash is therefore -$5,135,000.
Cash Flow
| 2016 | 41.41M | -68.96M | 25.94M |
|---|---|---|---|
| 2017 | -12.42M | 25.91M | -1.03M |
| 2018 | -13.22M | -36.58M | 110.37M |
| 2019 | -60.14M | 16.96M | 7.41M |
| 2020 | 29.99M | 58.30M | 40.08M |
| 2021 | -62.34M | -99.25M | 42.5M |
| 2022 | -59.55M | 22.75M | 31.66M |
SURF Cash Flow Statement (2016 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 57.64M | 176.73M | 48.35M | 84.11M | 23.54M | 9.99M | 12.69M |
Operating activities | |||||||
Net income | -63.58M | -78.48M | 59.33M | -54.78M | -6.59M | -45.37M | -17.45M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 1.36M | 1.56M | 1.67M | 1.78M | 1.34M | 964K | 331K |
Stock-based compensation expense | 7.22M | 8.54M | 7.76M | 5.99M | 5.21M | 4.70M | 1.34M |
| Deferred income tax benefit | 7.22M | 8.54M | 7.76M | 5.99M | 5.21M | 4.70M | 1.34M |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -1.30M | -226K | -2.71M | 583K | 23K | 285K | 1.8M |
Cash generated by operating activities | -59.55M | -62.34M | 29.99M | -60.14M | -13.22M | -12.42M | 41.41M |
Investing activities | |||||||
Purchases Of Investments | -40.19M | -111.63M | -650K | -118.34M | -107.25M | 0 | -97.04M |
Investments In Property Plant And Equipment | -497K | -120K | -43K | -1.53M | -2.01M | -1.97M | -836K |
Acquisitions Net | 0 | 0 | 0 | -16.96M | 36.58M | 0 | 0 |
Cash generated by investing activities | 22.75M | -99.25M | 58.30M | 16.96M | -36.58M | 25.91M | -68.96M |
Financing activities | |||||||
Common Stock Issued | 31.37M | 29.52M | 29.08M | 24K | 111.94M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 31.66M | 42.5M | 40.08M | 7.41M | 110.37M | -1.03M | 25.94M |
Net Change In Cash | -5.13M | -119.09M | 128.38M | -35.76M | 60.57M | 12.46M | -1.61M |
Cash at end of period | 52.50M | 57.64M | 176.73M | 48.35M | 84.11M | 22.45M | 11.08M |
| Data source | Data source | Data source | Data source | Data source |